Evoke Pharma (EVOK)
(Real Time Quote from BATS)
$5.16 USD
+0.65 (14.41%)
Updated Sep 23, 2024 03:54 PM ET
After-Market: $5.26 +0.10 (1.94%) 4:10 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EVOK 5.16 +0.65(14.41%)
Will EVOK be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for EVOK based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for EVOK
Nantahala Capital Management's Recent Transaction in Evoke Pharma Inc
Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments
Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference
Evoke Pharma to Present at H.C. Wainwright?s 26th Annual Global Investment Conference
Evoke Pharma files for $50M mixed securities shelf